<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Joachim</forename><forename type="middle">B</forename><surname>Kunz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Rausch</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory" key="lab1">European Molecular Biology Laboratory (EMBL)</orgName>
								<orgName type="laboratory" key="lab2">Genome Biology Unit</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">Genomics Core Facility</orgName>
								<orgName type="laboratory">European Molecular Biology Laboratory (EMBL)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Obul</forename><forename type="middle">R</forename><surname>Bandapalli</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Juliane</forename><surname>Eilers</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paulina</forename><surname>Pechanska</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><surname>Schuessele</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yassen</forename><surname>Assenov</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Epigenomics and Cancer Risk Factors</orgName>
								<orgName type="department" key="dep2">The German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adrian</forename><forename type="middle">M</forename><surname>Stütz</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory" key="lab1">European Molecular Biology Laboratory (EMBL)</orgName>
								<orgName type="laboratory" key="lab2">Genome Biology Unit</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Kirschner-Schwabe</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology/Hematology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jana</forename><surname>Hof</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology/Hematology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">German Cancer Consortium (DKTK)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cornelia</forename><surname>Eckert</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology/Hematology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arend</forename><surname>Von Stackelberg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Schrappe</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology/Hematology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig-Holstein</orgName>
								<address>
									<addrLine>Campus Kiel</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stanulla</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Pediatric Hematology/Oncology</orgName>
								<orgName type="institution">Medical School Hannover</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rolf</forename><surname>Koehler</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Human Genetics</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Smadar</forename><surname>Avigad</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Molecular Oncology</orgName>
								<orgName type="department" key="dep2">Felsenstein Medical Research Center and Pediatric Hematology Oncology</orgName>
								<orgName type="institution">Schneider Children&apos;s Medical Center of Israel</orgName>
								<address>
									<settlement>Petah Tikva</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sarah</forename><surname>Elitzur</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Molecular Oncology</orgName>
								<orgName type="department" key="dep2">Felsenstein Medical Research Center and Pediatric Hematology Oncology</orgName>
								<orgName type="institution">Schneider Children&apos;s Medical Center of Israel</orgName>
								<address>
									<settlement>Petah Tikva</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rupert</forename><surname>Handgretinger</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University Hospital Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vladimir</forename><surname>Benes</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Genomics Core Facility</orgName>
								<orgName type="laboratory">European Molecular Biology Laboratory (EMBL)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joachim</forename><surname>Weischenfeldt</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory" key="lab1">European Molecular Biology Laboratory (EMBL)</orgName>
								<orgName type="laboratory" key="lab2">Genome Biology Unit</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><forename type="middle">O</forename><surname>Korbel</surname></persName>
							<email>jan.korbel@embl-heidelberg.de</email>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory" key="lab1">European Molecular Biology Laboratory (EMBL)</orgName>
								<orgName type="laboratory" key="lab2">Genome Biology Unit</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martina</forename><forename type="middle">U</forename><surname>Muckenthaler</surname></persName>
							<email>martina.muckenthaler@med.uni-heidelberg.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Molecular Medicine Partnership Unit</orgName>
								<orgName type="institution">EMBL-University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><forename type="middle">E</forename><surname>Kulozik</surname></persName>
							<email>andreas.kulozik@med.uni-heidelberg.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Oncology, Hematology and Immunology</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">3E8F943A29A6350E8A530F3C8AFF3265</idno>
					<idno type="DOI">10.3324/haematol.2015.129692</idno>
					<note type="submission">received on April 24, 2015. Manuscript accepted on August 11, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Relapsed precursor T-cell acute lymphoblastic leukemia is characterized by resistance against chemotherapy and is frequently fatal.</s><s>We aimed at understanding the molecular mechanisms resulting in relapse of T-cell acute lymphoblastic leukemia and analyzed 13 patients at first diagnosis, remission and relapse by whole exome sequencing, targeted ultra-deep sequencing, multiplex ligation dependent probe amplification and DNA methylation array.</s><s>Compared to primary T-cell acute lymphoblastic leukemia, in relapse the number of single nucleotide variants and small insertions and deletions approximately doubled from 11.5 to 26.</s><s>Targeted ultra-deep sequencing sensitively detected subclones that were selected for in relapse.</s><s>The mutational pattern defined two types of relapses.</s><s>While both are characterized by selection of subclones and acquisition of novel mutations, 'type 1' relapse derives from the primary leukemia whereas 'type 2' relapse originates from a common pre-leukemic ancestor.</s><s>Relapse-specific changes included activation of the nucleotidase NT5C2 resulting in resistance to chemotherapy and mutations of epigenetic modulators, exemplified by SUZ12, WHSC1 and SMARCA4.</s><s>While mutations present in primary leukemia and in relapse were enriched for known drivers of leukemia, relapse-specific changes revealed an association with general cancer-promoting mechanisms.</s><s>This study thus identifies mechanisms that drive progression of pediatric T-cell acute lymphoblastic leukemia to relapse and may explain the characteristic treatment resistance of this condition.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes that accounts for about 15% of pediatric acute lymphoblastic leukemias <ref type="bibr" target="#b0">1</ref> and can be cured in approximately 80% of affected children <ref type="bibr">.2,3</ref></s><s>However, relapsed T-ALL is highly resistant to chemotherapy <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> and patients who experience a relapse face a dismal prognosis. <ref type="bibr" target="#b4">5</ref></s><s>In B-cell precursor (BCP)-ALL, integrated genomic analysis identified relapse-specific signatures of gene expression, somatic copy number alterations (CNA) and promoter methylation. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s>imilar observations in relapsed T-ALL are scarce: gene expression analysis revealed that relapsed T-ALL is characterized by a gene response pattern that is also found in early, but not in late relapse of BCP-ALL. <ref type="bibr" target="#b7">8</ref></s><s>Genome-wide analysis in relapsed T-ALL, in contrast to relapsed BCP-ALL, found simi-lar numbers of CNA as those in matched samples taken during the primary disease. <ref type="bibr" target="#b8">9</ref></s><s>While DNA methylation in T-ALL has been shown to differ from that in BCP-ALL, <ref type="bibr" target="#b9">10</ref> systematic comparisons of DNA methylation between primary and relapsed T-ALL are not available.</s><s>Evolution into relapsed T-ALL has been attributed to clonal selection, because relapsespecific rearrangements of the T-cell receptor were backtracked to primary disease <ref type="bibr" target="#b10">11</ref> and because leukemic cells from primary disease can develop into a clone resembling relapsed disease after transfer into immunodeficient mice. <ref type="bibr" target="#b11">12</ref></s><s>Rarely, late relapse of T-ALL represents a true secondary leukemia, whereby an underlying genetic predisposition could be documented in at least one patient. <ref type="bibr" target="#b12">13</ref></s><s>o obtain a more comprehensive picture of the evolution of T-ALL from primary disease to relapse we performed an integrated genomic analysis of 13 patients with T-ALL, who were</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients' clinical characteristics</head><p><s>Patients were treated according to ALL-BFM 2000 or related frontline protocols (INS-89, INS-98, 14 IC 15 ).</s><s>One patient was aged 18 at diagnosis, all others were children or adolescents.</s><s>The 13 patients (Table <ref type="table" target="#tab_0">1</ref>) were recruited between 1993 and 2007 from the ALL-REZ BFM 2002 trials (patients T-ALL-H-A61, -E114, -F110, -KI17, -MD40, -T92, -T128) or from Schneider Children's Medical Center of Israel, Petah Tikva, Israel (patients T-ALL-H-S00169, -S00207, -S00285, -S00438, -S00456, -S00472) and selected on the basis of sufficient material being available from the time points of first diagnosis, remission and relapse.</s><s>Minimal residual disease (MRD) response was assessed as described previously <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b15">16</ref> (Online Supplementary Table <ref type="table" target="#tab_2">S3</ref>).</s></p><p><s>This study was approved by the institutional review boards of the Charité Universitätsmedizin Berlin and the Medical Faculty Heidelberg.</s><s>Informed consent was obtained in accordance with the Declaration of Helsinki.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exome capture, target capture and Illumina sequencing</head><p><s>The Agilent SureSelect Target Enrichment Kit (Agilent, Santa Clara, CA, USA; vendor's protocol version 2.0.1) was used to capture all human exons for sequencing.</s><s>The HaloPlex Target Enrichment Kit (Agilent, Santa Clara, CA, USA; vendor's protocol version D.5, May 2013) was used according to the manufacturer's instructions.</s><s>The starting material consisted of 225 ng of genomic DNA.</s><s>The captured fragments were sequenced as 100 bp paired reads using an Illumina HiSeq instrument (Illumina, San Diego, CA, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of whole exome sequencing and targeted ultra-deep sequencing data</head><p><s>The analysis of sequencing data is detailed in the Online Supplementary Methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA methylation analysis using 450k BeadChip arrays</head><p><s>Genomic DNA (200 ng) was bisulfite-converted using the EZ DNA Methylation Gold Kit (Zymo Research, Irvine, CA, USA).</s><s>The Infinium methylation assay (Illumina) was carried out as previously described. <ref type="bibr" target="#b16">17</ref></s><s>Data from the 450k Human Methylation Array were normalized by the Beta Mixture Quantile (BMIQ) method <ref type="bibr" target="#b17">18</ref> using the RnBeads analysis software package. <ref type="bibr" target="#b18">19</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multiplex ligation dependent probe amplification</head><p><s>Multiplex ligation dependent probe amplification (MLPA) was done using the MRC Holland (Amsterdam, The Netherlands) SALSA MLPA probe mix P383-A1 T-ALL according to the manufacturer's instructions.</s><s>Polymerase chain reaction products were separated by capillary electrophoresis on an ABI-3130XL device; the size standard was GeneScan 500-250 (Applied Biosystems).</s><s>Coffalyser software, available at http://www.mlpa.com,</s><s>was used for the analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated analysis</head><p><s>In order to evaluate functions that were altered by mutation or DNA methylation at relapse, Ingenuity Evolution of pediatric T-ALL into relapse haematologica | 2015; 100 (11) Pathway Analysis (IPA, Version 21249400; Qiagen, Redwood City, CA, USA) was used.</s><s>For details refer to the Online Supplementary Methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relapsed T-cell acute lymphoblastic leukemia acquires single nucleotide variants and small insertions and deletions</head><p><s>We performed whole exome sampling (WES) of DNA samples obtained from 13 patients (see Table <ref type="table" target="#tab_0">1</ref> for clinical characteristics) at the time of first diagnosis, during remission and at relapse, and identified a total of 340 somatic single nucleotide variants (SNV) and 53 small insertions and deletions (InDels; Online Supplementary Table <ref type="table" target="#tab_0">S1</ref>).</s><s>On average, each leukemia specimen carried 11.5 (SD 7.0) somatic SNV and InDels at first diagnosis and 26.0 (SD 26.6) somatic SNV and InDels at the time of relapse -suggesting ongoing evolution of the major clone or of minor subclones.</s><s>Only 85 of 126 SNV and 14 of 23 InDels present at the time of first diagnosis could also be detected in the corresponding relapse sample, indicating that the (treatment-related) eradication of leukemic clones contributes to the evolution of relapse.</s><s>We defined a mutation as "relapse-specific" if it was detected by WES or MLPA in a relapse sample, but not in the corresponding primary leukemia sample from the same patient.</s><s>This could include mutations that were detected in the primary leukemia of other patients.</s></p><p><s>Comparing all mutations in primary disease to those in relapse, no significant difference in the types of single nucleotide exchanges and in the ratio of transversions and transitions was identified (Online Supplementary Figure <ref type="figure" target="#fig_0">S1A</ref>).</s><s>However, mutations at the central position of the trinucleotides TCA and GCT were significantly more frequent among relapse-specific SNV than in primary leukemia (Online Supplementary Figure <ref type="figure" target="#fig_0">S1B,C</ref>), consistent with a contribution of cytarabine to the acquisition of mutations during treatment. <ref type="bibr" target="#b19">20</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Somatic copy number alterations can represent subclonal, "late" events</head><p><s>We used MLPA in order to identify CNA in genes commonly altered in T-ALL.</s><s>On average, 3.5 CNA were detected in each primary leukemia sample and 3.2 in each relapse sample, whereas 2.7 CNA were detected in both samples from the same patient (Online Supplementary Table <ref type="table" target="#tab_1">S2</ref>).</s><s>Most commonly, we found deletions of the CDKN2A/B locus 21 on chromosome 9q (all patients), followed by microdeletions within the LEF1 gene 22 (6/13 patients), amplification of the MYB gene <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref> (4/13 patients), deletions of the PTEN gene <ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b25">26</ref> (3/13 patients) and homozygous deletions of the PTPN2 gene <ref type="bibr" target="#b26">27</ref> (2/13 patients).</s><s>Thirty-five of the 45 CNA that were identified in primary disease were preserved in relapse, a proportion comparable to the corresponding numbers of SNV and InDels.</s><s>In four patients, CNA found to be lost in relapse affected the CDKN2A, LEF1 or PTEN genes, indicating that the deletion of these tumor suppressors can be a late event during leukemogenesis.</s><s>Although several CNA (deletions of SUZ12, LEF1, PTEN, CASP8AP2; amplification of MYB) were specific for relapse in individual patients, none of these was specific for relapse in more than one patient or significantly enriched in either primary disease or relapse.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Targeted ultra-deep sequencing detects rare subclones</head><p><s>In order to track the clonal evolution of the relapses, we performed targeted ultra-deep sequencing of all mutations that had previously been identified by WES using the HaloPlex target capture (Agilent).</s><s>Allele frequencies inferred by HaloPlex were highly reproducible (Online Supplementary Figure <ref type="figure">S2A</ref>) and corresponded well to allele frequencies inferred by WES (Online Supplementary Figure <ref type="figure">S2B</ref>).</s><s>We analyzed whether HaloPlex reflected the frequencies of rare alleles by measuring the signals in serial dilutions.</s><s>This analysis indicated that the allele frequency is highly correlated with the dilution (r=0.91).</s><s>With increasing dilution and decreasing allele frequencies the accuracy of quantification of allele frequencies dropped because mutant reads were overrepresented (Online Supplementary Figure <ref type="figure">S2C</ref>).</s><s>Rare alleles were identified by comparing allele frequencies in the sample of interest with a reference pool consisting of healthy control DNA and unrelated leukemia samples.</s><s>This technique sensitively detected alleles with a frequency in the range of 0.01 and below: 91% of leukemia-specific SNV were detected after diluting leukemia DNA in control DNA at a ratio of 10 -2 , 26% were detected in a dilution of 10 -3 and 3% in a dilution of 10 -4 .</s><s>The rate of SNV that were detected as false positives in samples from patients who never carried the respective SNV was 1.8% (Online Supplementary Figure <ref type="figure">S2D</ref>), indicating that the detection of a significant proportion of mutant reads by HaloPlex is a reliable qualitative indicator of a small subclone carrying the mutation of interest.</s><s>The greatest sensitivity of detection was achieved for insertions of more than one nucleotide.</s><s>For example, in patient's S00169 remission sample two reads carrying a specific 9 bp insertion in the NOTCH1 gene among 43,567 total reads covering this region indicated persistent MRD in the order of 10 -4 (Online Supplementary Table <ref type="table">S6</ref>).</s></p><p><s>In ten of 13 patients we found at least one SNV that had developed from a rare (&lt;0.05) subclonal allele in primary disease to a major clonal allele in relapse (Online Supplementary Table <ref type="table">S5</ref>).</s><s>Of the 211 SNV and 30 InDels which were found in the major clone exclusively in relapse by WES, 45 and nine, respectively, were detected at a low allele frequency already in primary disease (Online Supplementary Table <ref type="table">S7</ref>).</s><s>The average allele frequency for such relapse-specific mutations found to be subclonal in primary leukemia was 0.006 (range, 0.0002-0.036).</s><s>Fiftyfive SNV and InDels present in the major clone at primary disease had been lost during the transition to relapse.</s><s>Fifty-four of these 55 mutations were not detected even in minor clones at the time of relapse, indicating that these clones were eradicated fully or at least to a level below the sensitivity of the HaloPlex analysis.</s></p><p><s>In ten of 13 of the first disease/relapse pairs a DNA sample obtained at the time of remission (for 7 patients, MRD level from the same sample was available and ≤ 10 -2 , Table <ref type="table" target="#tab_0">1</ref>) was also available for ultra-deep sequencing.</s><s>In these samples we searched for the presence of SNV that had been detected in the same patient at the time of either primary disease or relapse.</s><s>In six patients (T-ALL-H-E114, -MD40, -KI17, -S00169, -S00285, -S00472) we detected a total of 52 (range, 1 -21) SNV or InDels, which were significantly more abundant in the remission samples than in the reference consisting of the average of all samples from healthy controls and from patients who never carried the respective SNV of interest (Online Supplementary Table <ref type="table">S6</ref>).</s><s>Allele frequencies in remission samples ranged between 0.00005 and 0.0095.</s><s>By comparison with a dilution series of leukemia samples in healthy DNA we estimate that these allele frequencies correspond to a frequency of leukemic cells of 0.0001 to 0.01 (1:10,000 -1:100), consistent with the MRD levels that were available (Table <ref type="table" target="#tab_0">1</ref>).</s><s>All of the mutations detected in remission samples were also found in the corresponding relapse sample with an allele frequency in the range of 0.13 to 0.91.</s><s>Thirteen mutations that were detectable in remission were already found in a major clone (allele frequency 0.22-0.93)</s><s>at primary disease, and an additional ten SNV were detected in primary disease samples at low allele frequencies (range, 0.0003 -  <ref type="figure">A, C</ref>) Variant allele frequencies in relapse were plotted over the variant allele frequency in the corresponding primary leukemia sample.</s><s>Allele frequencies were determined by HaloPlex sequencing, only in the rare case that a certain allele was not covered by HaloPlex, allele frequencies from WES were used.</s><s>(B, D) The simplified models show each mutation as a single symbol (circle, square, pentagon, ellipse).</s><s>Blue symbols denote mutations that were detected in the major clone of primary leukemia, red symbols denote mutations that were specific for relapse.</s><s>(A, B) Type 1 relapse: all mutations present in the major clone from primary disease were also present in relapse.</s><s>The clone giving rise to relapse carried all mutations that were detected in the major clone of primary leukemia.</s><s>(C, D) Type 2 relapse: the major clone from primary leukemia was lost in relapse, as indicated by the mutations that were present in the major clone in primary leukemia but absent in relapse.</s><s>The clone giving rise to relapse shared some but not all mutations with the major clone of primary leukemia and was derived from a common ancestor, but evolved independently already before the initial diagnosis.</s><s>A B C D 0.0120).</s><s>Twenty-six SNV that were detected in remission were not detected in the corresponding primary disease sample with a sensitivity of 0.01 or higher.</s><s>We propose that these 26 SNV may have originated from a mutational event during treatment, although clonal selection starting from a very small subclone present at initial diagnosis cannot be ruled out.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evolution of pediatric T-ALL into relapse</head><p><s>In all 13 patients a minimal set of common genetic changes (at least one concordant MRD marker, Online Supplementary Table <ref type="table" target="#tab_2">S3</ref>, or at least six concordant SNV and InDels, Figure <ref type="figure" target="#fig_0">1</ref>) were found in both the primary leukemia and relapse samples, which indicated that all relapses were bona fide recurrences of the leukemia and not a second, unrelated neoplasm (as has previously been described in a small proportion of relapsed patients based on the identification of discordant MRD markers <ref type="bibr" target="#b12">13</ref> ).</s><s>By analyzing allele frequency plots, we can distinguish two types of relapse: type 1 and type 2. Type 1 relapse, observed in six of 13 patients (Figure <ref type="figure" target="#fig_0">1A,B</ref>), contained all mutations that were already detectable at the time of primary leukemia.</s><s>This type of relapse developed either from a major subclone or from a smaller subclone that had acquired additional mutations late in the process of leukemogenesis.</s><s>In type 2 relapse, observed in the remaining seven patients, mutations that had been present in the major clone in primary leukemia were lost at relapse (Figure <ref type="figure" target="#fig_0">1C,D</ref>).</s><s>Here, relapse developed from an ancestral pre-leukemic clone that had already diverged into distinguishable subclones at an early time point prior to the initial diagnosis.</s><s>In both types of relapse, clonal selection and acquisition of novel mutations contributed to the mutational load.</s><s>Type 1 showed a trend to be more frequent in early relapses (time to relapse &lt;24 months; P=0.07, see Online Supplementary Figure <ref type="figure">S3</ref> for a logistic regression model) and in Israeli and Palestinian patients (P=0.029,</s><s>Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>The example of mutations in the nucleotidase NT5C2 illustrates the genetic plasticity of T-ALL.</s><s>NT5C2 mutations were identified in five of 13 relapse samples (R367Q in patients A61, S00207, S00285, T92; D407Y in patient T92; P414S in S00456; Online Supplementary Tables <ref type="table" target="#tab_0">S1 and  S5</ref>).</s><s>R367Q has been shown to activate the nucleotidase activity of NT5C2 and to confer resistance against nucleoside analogs. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref></s><s>In two patients, an NT5C2 mutation was already detected in primary disease samples at low allele frequency (A61: D407Y, allele frequency 0.3%; S00456: P414S, allele frequency 0.1%).</s><s>While patient S00456 carried the same mutation in the corresponding relapse sample, patient A61 lost the D407Y mutation and acquired the R367Q mutation.</s><s>NT5C2 mutations were clonal in three relapses, but subclonal in two other relapse samples (S00207: allele frequency 0.1; T92: allele frequencies 0.41 for R367Q and 0.09 for D407Y).</s><s>This is compatible with the notion that acquisition of resistance to chemotherapy by NT5C2 activation can be a late, not-initiating event on the way to relapse.</s></p><p><s>Patient E114 demonstrated that the evolution of the relapse-specific clone from a pre-leukemic ancestor may be facilitated by intensive induction treatment of the primary leukemia.</s><s>In this patient, two preserved MRD markers confirmed the relationship between primary leukemia and relapse.</s><s>In addition, targeted ultra-deep sequencing identified five mutations that had been present at a subclonal level in primary disease, persisted in remission and became predominant in relapse (Figure <ref type="figure" target="#fig_0">1C</ref>, Online Supplementary Tables <ref type="table">S6 and S7</ref>).</s><s>Already in the remission sample, which was taken immediately after induction treatment had been completed, 16 newly acquired mutations were detected and later predominated at relapse (Online Supplementary Table <ref type="table">S6</ref>).</s><s>During the 2 years of remission before relapse occurred, only five more mutations accumulated.</s><s>Interestingly, although MLPA identified deletion of CDKN2A/B and amplification of MYB in the primary disease sample of this patient (Online Supplementary Table <ref type="table" target="#tab_1">S2</ref>), none of them was conserved between primary disease and relapse, indicating that in this specific leukemia these copy number variants were probably not the initiating event in leukemogenesis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relapse-specific alterations in T-acute lymphoblastic leukemia do not show association with leukemogenesis, but with cancerogenesis in general</head><p><s>In nine of 13 patients we identified relapse-specific mutations that, based on current knowledge, are likely to contribute to the evolution of relapse (Table <ref type="table" target="#tab_2">3</ref>).</s><s>Besides known mechanisms of leukemogenesis in T-ALL such as NOTCH-activation or MYB-amplification, the most common alterations were mutations activating the nucleotidase NT5C2 and mutations in epigenetic modifiers, such as WHSC1, SUZ12, SMARCA4, ARID4B and USP7.</s></p><p><s>In order to obtain an unsupervised view of the contribution of mutations to relapse we investigated whether the genetic alterations that are specific for relapse can be linked to certain biological functions.</s><s>To this end, we grouped genetic alterations, which had been detected either by WES or by MLPA, according to the time points at which they were found.</s><s>Using Ingenuity Pathway Analysis (IPA) software, genes that were mutated or deleted in the major clones at both times, primary leukemia and relapse, were compared to those genes that were found to be mutated or deleted in the major clone at relapse but not in the corresponding primary leukemia (Online Supplementary Table <ref type="table">S8</ref>).</s></p><p><s>Using genes altered both in primary leukemia and in relapse, IPA constructed a dense network involving the nodes NOTCH, IL7R, MTOR, GATA3 and AKT, reflecting the frequent occurrence of somatic DNA alterations in established leukemia drivers in this gene set (Online Supplementary Figure <ref type="figure">S4A</ref>; Table <ref type="table" target="#tab_3">4</ref>).</s><s>In contrast, the genes that were mutated in a relapse-specific way showed similarities to gene lists typically carrying somatic mutations in gastrointestinal and other cancers, but not leukemia (Online Supplementary Figure <ref type="figure">S4B</ref>; Table <ref type="table" target="#tab_3">4</ref>).</s><s>These findings suggest that relapsed T-ALL share a profile of mutations with non-hematologic cancers.</s><s>Among genes that were mutated in a relapse-specific manner, we did not observe a strong enrichment of canonical pathways (minimal P=0.003 for actin cytoskeleton signaling).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypermutation caused by somatic DNA repair deficiency can contribute to genetic instability in relapsed T-cell acute lymphoblastic leukemia</head><p><s>Patient S00285 carried a moderate number of eight mutations in primary disease, but an extraordinarily high number of 106 mutations in relapse, many of which were subclonal (Online Supplementary Tables <ref type="table" target="#tab_0">S1 and S5</ref>).</s><s>One of the 102 relapse-specific mutations affected the BLM gene.</s><s>While this mutation was not present at the time of primary disease, it was the most abundant newly acquired mutation in remission and present in the main clone at relapse.</s><s>BLM codes for a RecQ DNA helicase and is required for DNA replication and DNA repair.</s><s>Inactivating germline mutations in BLM cause Bloom syndrome, a recessively inherited tumor predisposition syndrome (OMIM #210900).</s><s>The K39N mutation observed in this patient is predicted to be damaging by PolyPhen <ref type="bibr" target="#b29">30</ref> and likely caused a somatic DNA-repair defect, resulting in the accumulation of a large number of mostly subclonal mutations during treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypomethylated promoters in relapsed T-cell acute lymphoblastic leukemia do not show association with leukemogenesis, but with cancerogenesis in general</head><p><s>We used Illumina 450k arrays to compare DNA methylation in relapse samples to that in the corresponding primary T-ALL samples.</s><s>In contrast to the situation in relapsed BCP-ALL, <ref type="bibr" target="#b5">6</ref> the average degree of methylation in relapse did not differ from average methylation in primary leukemia (Figure <ref type="figure">2A</ref>, r=0.996).</s><s>When primary disease and relapse samples from individual patients were compared, both hypo-and hypermethylation of promoters in relapse could be observed (Figure <ref type="figure">2B</ref>).</s></p><p><s>In order to identify promoters that may undergo differential methylation in relapse, we filtered for promoters that: (i) were represented on the 450k array by at least three different probes; (ii) had a gene symbol assigned; and (iii) had a decrease or an increase of the β-value of at least 0.2 in absolute numbers in at least three different patients.</s><s>According to these criteria, a total of 239 promoters were recurrently hypermethylated and 579 promoters recurrently hypomethylated in relapse.</s><s>The lists of hyper-and hypomethylated promoters (Online Supplementary Table <ref type="table">S8</ref>) were subjected to IPA.</s><s>The association of hypermethylated promoters with diseases and functions reached marginal significance for one functional category only (P=6.62 <ref type="bibr">-5</ref> for "development of neurons").</s><s> ) and endometrial carcinoma (P=1.92x10</s><s>-9 ; Table <ref type="table" target="#tab_3">4</ref>).</s><s>We did not observe a strong enrichment of canonical pathways (minimal P=0.003 for glutamate receptor signaling) among promoters that were hypomethyled in a relapse-specific manner.</s><s>Although the lack of RNA samples precludes an analysis of a correlation between methylation and gene expression data, our results show that DNA methylation changes may cooperate with mutational events in driving T-ALL relapse.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>By applying a deep coverage target enrichment technique to sensitively and quantitatively detect rare mutations in primary disease, remission and relapse of pediatric T-ALL, we distinguish between relapses arising from the major clone of the primary leukemia (type 1) and relapses arising from a pre-leukemic ancestral clone (type 2).</s><s>In both types, selection of subclones and acquisition of novel mutations contributed to clonal evolution.</s><s>Similar observations have been made before for BCP-leukemia <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b8">9</ref> and for acute myeloid leukemia. <ref type="bibr" target="#b30">31</ref></s><s>The size of the subclones that later gave rise to relapse can be estimated to range between 1:100 and 1:1,000 of the primary leukemia in our series.</s><s>The association of type 1 relapse with a short duration of remission may intuitively be explained by a relative resistance of the primary leukemia to treatment.</s><s>The more frequent occurrence of type 1 relapses in the Israeli/Palestinian group of patients is unlikely to be related to differences of treatment, because the protocols used in Israel and in Germany are very similar and give comparable overall results. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b13">14</ref></s><s>ore than three-quarters (187 of 241) of relapse-specific mutations could not be detected in primary disease samples despite a sensitivity of detection that exceeded 1:100 for most mutations.</s><s>The mutational load during relapse is more than doubled compared to that during primary leukemia, suggesting that mutations are truly acquired de novo during treatment and/or during remission.</s><s>Relapsespecific patterns of mutations attributed to chemotherapy have been described by others. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b30">31</ref></s><s>Comparing relapse-spe-cific mutations to mutations in primary leukemia, we found a significant increase in single nucleotide exchanges at the central position of the trinucleotide sequence TCA, a mutational signature that has been attributed to the mutagenic effects of cytarabine. <ref type="bibr" target="#b19">20</ref></s><s>However, the overall mutational pattern changed only slightly in relapse, indicating that the contribution of chemotherapy to the acquisition of mutations may be minor in this cohort of patients.</s></p><p><s>The leukemia that acquired a BLM mutation during treatment was of particular interest.</s><s>This mutation first appeared at the time of remission and was clonal at the time of relapse.</s><s>The presence of this mutation was associated with an unusually high number of mostly subclonal relapse-specific mutations, indicating that acquired mutations of DNA repair genes may result in somatic hypermutation during the clonal evolution of T-ALL.</s><s>While haploinsufficiency is not evident in heterozygous carriers of germline BLM mutations, <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33</ref> the effect of somatic BLM mutations in the context of leukemia may be amplified by mutagenic stress induced by chemotherapy.</s></p><p><s>While the genetic alterations shared by primary leukemia and relapse are, as expected, enriched in genes that are known to be implicated in leukemogenesis, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b33">34</ref> the genes that we specifically found to be mutated in T-ALL relapse are not enriched for leukemia-specific genes.</s><s>Relapse-specific genes are more closely related to other cancer types, implying that relapsed T-ALL, in addition to the genetic repertoire required to induce leukemia in T cells, have acquired properties that are linked to cancer in a less specific sense.</s><s>Potentially, these genes contain a previously unrecognized category of genes that are specific for T-ALL relapses.</s><s>These observations suggest that the type of malignancy is determined by the early genetic changes of the normal hematopoietic precursor and that the progression may be driven by more general abnormalities of carcinogenesis.</s><s>These progression-related changes may also explain the clinical observation that relapsed T-ALL is frequently refractory to leukemia-directed chemotherapy.</s></p><p><s>An analysis of the 450k methylome data revealed that, in contrast to BCP-ALL, <ref type="bibr" target="#b5">6</ref> overall DNA methylation levels in T-ALL hardly differ between primary leukemia and relapse.</s><s>However, a set of promoters was found to be recurrently hypomethylated in relapse compared to primary disease.</s><s>This set contains many genes related to cancer, albeit not specifically involved in leukemogenesis.</s><s>The correlation between DNA methylation and RNA abundance could not be analyzed due to lack of RNA samples.</s><s>However, a strong inverse correlation between promoter methylation and RNA expression has been described before in ALL. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b9">10</ref></s><s>Hence, both relapse-specific mutations and changes of the DNA methylome are consistent with the activation of additional oncogenic mechanisms in relapsed T-ALL.</s><s>The importance of epigenetic changes is specifically highlighted by the findings in patient S00169 (Figure <ref type="figure" target="#fig_0">1A</ref>, Online Supplementary Table <ref type="table" target="#tab_0">S1</ref>), who suffered from a very early relapse and in whom the only detectable mutational difference between primary leukemia and relapse was the acquisition of the activating mutation E1099K in the H3K36 histone methyl transferase WHSC1.</s><s>This hotspot mutation has been recurrently reported in mantle cell lymphoma <ref type="bibr" target="#b34">35</ref> and in pediatric BCP-ALL <ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37</ref> and results in cellular transformation. <ref type="bibr" target="#b35">36</ref></s><s>The emergence of a clone carrying the WHSC1 E1099K mutation may have been sufficient to induce early relapse in this patient.</s></p><p><s>The only gene that was recurrently mutated in a relapsespecific manner was NT5C2, <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref> partially explaining the relative success in the use of nelarabine, which is not a substrate for NT5C2, in T-ALL relapse. <ref type="bibr" target="#b37">38</ref></s><s>In our small series of patients, no other mutation was recurrent and many mutations present in the primary leukemia were lost in relapse.</s><s>The application of novel, targeted therapies to patients with relapsed T-ALL will, therefore, likely require a thorough genetic characterization of relapse-specific targets.</s></p><p><s>In conclusion, the data presented here identify two molecularly defined types of relapse in pediatric T-ALL and implicate the selection of subclones, the acquisition of novel somatic mutations and the hypomethylation of promoters as mechanisms driving the progression of T-ALL from primary disease to relapse.</s><s>It is noteworthy that the relapsespecific alterations tend to activate general mechanisms of carcinogenesis rather than known leukemia-specific drivers.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>Ultra-deep sequence analysis of primary and relapsed T-ALL distinguishes two types of relapse.</s><s>(A, C) Variant allele frequencies in relapse were plotted over the variant allele frequency in the corresponding primary leukemia sample.</s><s>Allele frequencies were determined by HaloPlex sequencing, only in the rare case that a certain allele was not covered by HaloPlex, allele frequencies from WES were used.</s><s>(B, D) The simplified models show each mutation as a single symbol (circle, square, pentagon, ellipse).</s><s>Blue symbols denote mutations that were detected in the major clone of primary leukemia, red symbols denote mutations that were specific for relapse.</s><s>(A, B) Type 1 relapse: all mutations present in the major clone from primary disease were also present in relapse.</s><s>The clone giving rise to relapse carried all mutations that were detected in the major clone of primary leukemia.</s><s>(C, D) Type 2 relapse: the major clone from primary leukemia was lost in relapse, as indicated by the mutations that were present in the major clone in primary leukemia but absent in relapse.</s><s>The clone giving rise to relapse shared some but not all mutations with the major clone of primary leukemia and was derived from a common ancestor, but evolved independently already before the initial diagnosis.</s></p></div></figDesc><graphic coords="4,67.12,167.08,316.22,590.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Evolution of pediatric T-ALL into relapse haematologica | 2015; 100(11)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="8,77.47,65.42,438.58,212.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Clinical characteristics of the 13 T-ALL patients analyzed.</s></p></div></figDesc><table><row><cell>Patient ID:</cell><cell>A61</cell><cell>E114</cell><cell>F110</cell><cell>KI17</cell><cell>MD40</cell><cell>T92</cell><cell>T128</cell><cell cols="6">S00169 S00207 S00285 S00438 S00456 S00472</cell></row><row><cell>T-ALL-H-…</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gender</cell><cell>M</cell><cell>M</cell><cell>M</cell><cell>F</cell><cell>M</cell><cell>M</cell><cell>M</cell><cell>M</cell><cell>F</cell><cell>F</cell><cell>M</cell><cell>M</cell><cell>M</cell></row><row><cell>Age at diagnosis</cell><cell>11</cell><cell>7</cell><cell>2</cell><cell>5</cell><cell>4</cell><cell>3.5</cell><cell>2</cell><cell>4.4</cell><cell>5.5</cell><cell>9.6</cell><cell>18</cell><cell>12</cell><cell>9.2</cell></row><row><cell>(years)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time to relapse</cell><cell>15</cell><cell>29</cell><cell>11</cell><cell>7</cell><cell>29</cell><cell>14</cell><cell>47</cell><cell>6.0</cell><cell>17.1</cell><cell>25.1</cell><cell>16.7</cell><cell>16.6</cell><cell>10.4</cell></row><row><cell>(months)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">White blood cell count 256</cell><cell>112</cell><cell>803</cell><cell>2.1</cell><cell>157</cell><cell>83</cell><cell>202</cell><cell>92</cell><cell>83</cell><cell>74</cell><cell>4</cell><cell>465</cell><cell>167</cell></row><row><cell>at diagnosis (x10 9 /L)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Cell source in relapse BM</cell><cell>BM</cell><cell>PB</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell><cell>BM</cell></row><row><cell>Blast count</cell><cell>72</cell><cell>98</cell><cell>73</cell><cell>80</cell><cell>59</cell><cell>85</cell><cell>83</cell><cell cols="5">unknown unknown unknown unknown 80</cell><cell>83</cell></row><row><cell>in relapse (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Immune phenotype* cortical</cell><cell>mature</cell><cell>pre</cell><cell>mature</cell><cell>cortical</cell><cell>cortical</cell><cell>cortical</cell><cell>pre</cell><cell>mature</cell><cell>mature</cell><cell cols="2">cortical cortical</cell><cell>pre</cell></row><row><cell>Remission sample</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>time point (weeks</cell><cell>12</cell><cell>12</cell><cell>12</cell><cell>12</cell><cell>12</cell><cell>12</cell><cell>12</cell><cell>11</cell><cell>54</cell><cell>83</cell><cell>21</cell><cell>5</cell><cell>24</cell></row><row><cell>after diagnosis)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">MRD level in remission 10 -4</cell><cell>10 -4</cell><cell>neg</cell><cell>10 -2</cell><cell>neg</cell><cell>neg</cell><cell>neg</cell><cell>n.a.</cell><cell>n.a.</cell><cell>n.a.</cell><cell>n.a.</cell><cell>n.a.</cell><cell>n.a.</cell></row><row><cell>Risk group</cell><cell>MR</cell><cell>HR</cell><cell>HR</cell><cell>HR</cell><cell>MR</cell><cell>MR</cell><cell>HR</cell><cell>HR</cell><cell>HR</cell><cell>MR</cell><cell>MR</cell><cell>HR</cell><cell>HR</cell></row><row><cell>in primary disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Treatment protocol** ALL-</cell><cell>ALL-</cell><cell>ALL-</cell><cell>ALL-</cell><cell>ALL-</cell><cell>ALL-</cell><cell>ALL-</cell><cell>INS-89</cell><cell>INS-89</cell><cell>INS-98</cell><cell>IC</cell><cell>IC</cell><cell>IC</cell></row><row><cell></cell><cell cols="7">BFM 2000 BFM 2000 BFM 2000 BFM 2000 BFM 2000 BFM 2000 BFM 2000</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Outcome</cell><cell>died</cell><cell>died</cell><cell>died</cell><cell>died</cell><cell cols="2">CCR after died in</cell><cell>CCR</cell><cell>died</cell><cell>died</cell><cell>died</cell><cell>died</cell><cell>died</cell><cell>died</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>SCT</cell><cell cols="2">subsequent after</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4. relapse</cell><cell>SCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Type of relapse is associated with treatment and with time to relapse.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Type of relapse</cell><cell></cell></row><row><cell></cell><cell>type 1</cell><cell>type 2</cell><cell>P</cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell></row><row><cell>male</cell><cell>5</cell><cell>5</cell><cell></cell></row><row><cell>female</cell><cell>1</cell><cell>2</cell><cell>1</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;9</cell><cell>3</cell><cell>5</cell><cell></cell></row><row><cell>&gt;9</cell><cell>3</cell><cell>2</cell><cell>0.59</cell></row><row><cell>Time to relapse</cell><cell></cell><cell></cell><cell></cell></row><row><cell>(months)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;24</cell><cell>6</cell><cell>3</cell><cell></cell></row><row><cell>&gt;24</cell><cell>0</cell><cell>4</cell><cell>0.07</cell></row><row><cell>WBC at diagnosis (x10 9 /L)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;100</cell><cell>4</cell><cell>2</cell><cell></cell></row><row><cell>&gt;100</cell><cell>2</cell><cell>5</cell><cell>0.29</cell></row><row><cell>Risk group in primary disease</cell><cell></cell><cell></cell><cell></cell></row><row><cell>medium risk</cell><cell>2</cell><cell>3</cell><cell></cell></row><row><cell>high risk</cell><cell>4</cell><cell>4</cell><cell>1.0</cell></row><row><cell>Protocol</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ALL BFM 2000</cell><cell>1</cell><cell>6</cell><cell></cell></row><row><cell>INS89, INS98, IC</cell><cell>5</cell><cell>1</cell><cell>0.029</cell></row><row><cell>Outcome</cell><cell></cell><cell></cell><cell></cell></row><row><cell>dead</cell><cell>6</cell><cell>5</cell><cell></cell></row><row><cell>alive</cell><cell>0</cell><cell>2</cell><cell>0.46</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Mutational mechanisms likely contributing to relapse.For each patient, relapse-specific mutations or CNA are listed that, according to published evidence, are likely to contribute to leukemogenesis or to emergence of relapse.</s><s>No such mutations were observed in patients KI17, MD40 and T128.</s></p></div></figDesc><table><row><cell>Patient</cell><cell>Gene</cell><cell>Alteration</cell><cell cols="3">Evidence for subclonality Mechanism</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>in primary leukemia</cell></row><row><cell>A61</cell><cell>NT5C2</cell><cell>NM_012229:exon15:c.1100G&gt;A:p.R367Q</cell><cell></cell><cell>no</cell><cell>Chemotherapy resistance 28, 29</cell></row><row><cell>E114</cell><cell>FBXW7</cell><cell>NM_018315:exon8:c.1147A&gt;G:p.T383A</cell><cell></cell><cell>no</cell><cell>NOTCH1 activation 41, 42</cell></row><row><cell></cell><cell>NOTCH1</cell><cell>NM_017617:exon26:c.4775T&gt;C:p.F1592S</cell><cell></cell><cell>no</cell><cell>NOTCH1 activation 43</cell></row><row><cell></cell><cell>WT1</cell><cell>NM_001198552:exon6:c.423_424insT:p.R141fs</cell><cell></cell><cell>no</cell><cell>WT1 inactivation 44</cell></row><row><cell></cell><cell>SUZ12</cell><cell>Heterozygous deletion chr 17q11.2</cell><cell></cell><cell>no</cell><cell>PRC2 inactivation 45</cell></row><row><cell>T92</cell><cell>NT5C2</cell><cell>NM_012229:exon17:c.1219G&gt;T:p.D407Y</cell><cell></cell><cell>no</cell><cell>Chemotherapy resistance 28, 29</cell></row><row><cell>S00169</cell><cell>WHSC1</cell><cell>NM_133330:exon20:c.3295G&gt;A:p.E1099K</cell><cell></cell><cell>no</cell><cell>Histone methylation 35, 36</cell></row><row><cell>S00207</cell><cell>SMARCA4</cell><cell>NM_001128847:exon19:c.2896C&gt;T:p.R966W</cell><cell></cell><cell>yes</cell><cell>Chromatin remodeling 46</cell></row><row><cell>S00285</cell><cell>BLM</cell><cell>NM_000057:exon3:c.117G&gt;T:p.K39N</cell><cell></cell><cell>no</cell><cell>DNA repair defect 47</cell></row><row><cell></cell><cell>USP7</cell><cell>NM_003470:exon15:c.1663C&gt;T:p.R555W</cell><cell></cell><cell>no</cell><cell>DNA methylation 48</cell></row><row><cell></cell><cell>ARID4B</cell><cell>Frameshift by deletion</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">NM_001206794:Exon7:c.420_423delAATA:p.N141Efs*32</cell><cell>no</cell><cell>Chromatin remodeling 49</cell></row><row><cell></cell><cell>NT5C2</cell><cell>NM_012229:exon15:c.1100G&gt;A:p.R367Q</cell><cell></cell><cell>no</cell><cell>Chemotherapy resistance 28, 29</cell></row><row><cell>S00438</cell><cell>JAK3</cell><cell>NM_000215:exon11:c.1533G&gt;A:p.M511I</cell><cell></cell><cell>yes</cell><cell>JAK3 activation 50</cell></row><row><cell></cell><cell>NOTCH1</cell><cell cols="3">NM_017617:exon26:c.4811_4820delinsTCCCTCACGCTTGAGG: no</cell><cell>NOTCH1 activation 43</cell></row><row><cell></cell><cell></cell><cell>p.V1605Pfs*4</cell><cell></cell><cell></cell></row><row><cell>S00456</cell><cell>NT5C2</cell><cell>NM_012229:exon16:c.1240G&gt;A:p.P414S</cell><cell></cell><cell>yes</cell><cell>Chemotherapy resistance 28, 29</cell></row><row><cell>S00472</cell><cell>NOTCH1</cell><cell cols="3">NM_017617:exon34:c.7524_7534delCTTCCTCACCC:p.F2509Vfs* no</cell><cell>NOTCH1 activation 434343</cell></row><row><cell></cell><cell>MYB</cell><cell>Amplification chr 6q23.3</cell><cell></cell><cell>no</cell><cell>Oncogenic transcription factor</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Ingenuity Pathway Analysis.</s></p></div></figDesc><table><row><cell cols="2">Genes mutated in major clone of</cell><cell cols="2">Genes mutated in relapse</cell><cell cols="2">Recurrently hypomethylated</cell></row><row><cell cols="2">primary leukemia and of relapse (n=145)</cell><cell>only (n=182)</cell><cell></cell><cell>promoters (n=579)</cell><cell></cell></row><row><cell>Disease or function</cell><cell>P</cell><cell>Disease or function</cell><cell>P</cell><cell>Disease or function</cell><cell>P</cell></row><row><cell>T-cell leukemia</cell><cell>2.26E-18</cell><cell>adenocarcinoma</cell><cell>4.25E-14</cell><cell>melanoma</cell><cell>6.89E-15</cell></row><row><cell>Precursor T-cell</cell><cell>5.56E-18</cell><cell>colorectal carcinoma</cell><cell>1.16E-11</cell><cell>endometrium tumor</cell><cell>1.92E-09</cell></row><row><cell>lymphoblastic leukemia-lymphoma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Acute lymphocytic leukemia</cell><cell>9.77E-18</cell><cell cols="2">gastrointestinal adenocarcinoma 1.29E-11</cell><cell>morphology of nervous system</cell><cell>2.29E-09</cell></row><row><cell>Melanoma</cell><cell>4.10E-15</cell><cell>colon carcinoma</cell><cell>1.39E-11</cell><cell>endometrial cancer</cell><cell>3.04E-09</cell></row><row><cell>Acute leukemia</cell><cell>1.23E-13</cell><cell>gastrointestinal carcinoma</cell><cell>2.02E-11</cell><cell>endometrioid carcinoma</cell><cell>4.20E-09</cell></row><row><cell>Lymphoproliferative disorder</cell><cell>2.30E-13</cell><cell>colon cancer</cell><cell>3.31E-11</cell><cell cols="2">development of central nervous system 4.54E-09</cell></row><row><cell>Leukemia</cell><cell>2.55E-13</cell><cell>malignant solid tumor</cell><cell>4.25E-11</cell><cell>adenocarcinoma in endometrium</cell><cell>5.18E-09</cell></row><row><cell>Hematologic cancer</cell><cell>5.06E-13</cell><cell>melanoma</cell><cell>1.22E-10</cell><cell>development of body axis</cell><cell>1.05E-08</cell></row><row><cell>Bone marrow cancer</cell><cell>7.87E-13</cell><cell>gastrointestinal neoplasia</cell><cell>1.27E-10</cell><cell>uterine cancer</cell><cell>1.42E-08</cell></row><row><cell>Lymphocytic leukemia</cell><cell>8.54E-13</cell><cell>gastrointestinal tract cancer</cell><cell>1.39E-10</cell><cell>synaptic transmission</cell><cell>1.67E-08</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Genes that were found to be mutated or deleted by WES or MLPA both in primary disease and in relapse (n=145), genes that were found to be mutated or deleted by WES or MLPA only in relapse (n=182) and promoters that were found to be hypomethylated in at least three patients (n=579) were subjected to Ingenuity Pathway Analysis for associated functions and diseases (see Online Supplementary TableS8). The ten most significant associations are reported.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors would like to thank the following institutions for grants: German Consortium for</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authorship and Disclosures Information on authorship, contributions, and financial &amp; other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.</head><p><s>Evolution of pediatric T-ALL into relapse haematologica | 2015; 100 (11)  1449 The β value for each promoter in relapse was compared to that in primary leukemia.</s><s>Promoters with a β value in relapse that was at least 0.2 higher than in primary leukemia were considered to be hypermethylated.</s><s>Promoters with a β value in relapse that was at least 0.2 lower than in primary leukemia were considered to be hypomethylated.</s><s>Only promoters of those genes for which at least one gene symbol is assigned and which are represented by at least three probes on the 450k array are represented here.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Acute leukemia incidence and patient survival among children and adults in the United States</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Dores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Devesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Linet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Morton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="43" />
			<date type="published" when="2001">2001-2007. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Late MRD response determines relapse risk overall and in subsets of childhood Tcell ALL: results of the AIEOP-BFM-ALL 2000 study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schrappe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Valsecchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2077" to="2084" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Van Vlierberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pieters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Beverloo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Meijerink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="168" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children&apos;s Oncology Group study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Devidas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2142" to="2150" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Einsiedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stackelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hartmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">31</biblScope>
			<biblScope unit="page" from="7942" to="7950" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Hogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="5218" to="5226" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia</title>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Edmonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yergeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">6604</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children&apos;s Oncology Group study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bhojwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Moskowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="711" to="717" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Mullighan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Su</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="issue">5906</biblScope>
			<biblScope unit="page" from="1377" to="1380" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nordlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Backlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wahlberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Flohr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Koehler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1305" to="1313" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse</title>
		<author>
			<persName><forename type="first">E</forename><surname>Clappier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gerby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sigaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">208</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="653" to="661" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition</title>
		<author>
			<persName><forename type="first">T</forename><surname>Szczepanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Van Der Velden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Waanders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1643" to="1649" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Longterm results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98</title>
		<author>
			<persName><forename type="first">B</forename><surname>Stark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nirel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avrahami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="419" to="424" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fronkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mejstrikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Avigad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="989" to="997" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Breit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stanulla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Flohr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1151" to="1157" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Genomewide DNA methylation profiling using Infinium(R) assay</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bibikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epigenomics</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="177" to="200" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Teschendorff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marabita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lechner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="189" to="196" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Comprehensive analysis of DNA methylation data with RnBeads</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Assenov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lutsik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lengauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Methods</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1138" to="1140" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Fordham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Irving</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Allan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="491" to="494" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fizzotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cimino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pisegna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2685" to="2690" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Inactivation of LEF1 in T-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="2845" to="2851" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lahortiga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Keersmaecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Vlierberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="593" to="595" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children</title>
		<author>
			<persName><forename type="first">E</forename><surname>Clappier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cuccuini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalota</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1251" to="1261" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Palomero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Sulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cortina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1203" to="1210" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zuurbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Vuerhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1405" to="1413" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kleppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lahortiga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Chaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="530" to="535" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Relapsespecific mutations in NT5C2 in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Hogan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="290" to="294" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL</title>
		<author>
			<persName><forename type="first">G</forename><surname>Tzoneva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perez-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="368" to="371" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A method and server for predicting damaging missense mutations</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Adzhubei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peshkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Methods</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="248" to="249" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Larson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">481</biblScope>
			<biblScope unit="issue">7382</biblScope>
			<biblScope unit="page" from="506" to="510" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">BLM heterozygosity and the risk of colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="issue">5589</biblScope>
			<biblScope unit="page">2013</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Zauber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sabbath-Solitare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marotta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="719" to="729" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">PHF6 mutations in T-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Van Vlierberghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Palomero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Khiabanian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="338" to="342" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Landscape of somatic mutations and clonal evolution in mantle cell lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valdes-Mas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Navarro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">45</biblScope>
			<biblScope unit="page" from="18250" to="18255" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1386" to="1391" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Oyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="198" to="201" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation</title>
		<author>
			<persName><forename type="first">N</forename><surname>Gokbuget</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Basara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baurmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="3504" to="3511" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schrappe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Ludwig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="3310" to="3322" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95</title>
		<author>
			<persName><forename type="first">A</forename><surname>Moricke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zimmermann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="4477" to="4489" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors</title>
		<author>
			<persName><forename type="first">J</forename><surname>O'neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Strack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1813" to="1824" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Buonamici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Sulis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1825" to="1835" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Ferrando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="issue">5694</biblScope>
			<biblScope unit="page" from="269" to="271" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">WT1 mutations in T-ALL</title>
		<author>
			<persName><forename type="first">V</forename><surname>Tosello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Mansour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1038" to="1045" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ntziachristos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tsirigos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Vlierberghe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="298" to="301" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Huether</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">3630</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Enhanced tumor formation in mice heterozygous for Blm mutation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Goss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Risinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kordich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="issue">5589</biblScope>
			<biblScope unit="page" from="2051" to="2053" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The genomic landscape of hypodiploid acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Holmfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Diaz-Flores</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="242" to="252" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Eldin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Beaudet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1247" to="1259" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bains</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Heinrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Loriaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2144" to="2146" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
